Skip to content

Study · Not a test of the peptide alone · 2015

4 results

The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.

Tkalia IG, Vorobyova LI, Grabovoy AN, Svintsitsky VS, Tarasova TO

Experimental oncology1 Mar 2015Cited by 3 (Europe PMC)

PMID25804228 (opens in a new tab)DOI10.31768/2312-8852.2015.37(1):30-35 (opens in a new tab)PepBankPUB-25804228
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Efficacy outcome

    In rats receiving cisplatin plus triptorelin for ovarian tumors, two animals were cured, representing 22.2%.

    In plain wordsIn rats with ovarian tumors, cisplatin plus triptorelin cured two animals, representing 22.2%.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableTumor cure
    Study

    ratn = 9

    Wistar rats with transplanted ascites ovarian tumor
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Among animals treated by combination of cytostatic drug with triptorelin, two were cured (22.2%),
    2 context sentences
    Summary · context
    36 female Wistar rats, which underwent intraperitoneal transplantation of ascites OT (5×10(6) cells per animal), have been involved in the study.
    Summary · context
    Rats were distributed into 4 groups (9 rats in each group): group 1 - animals, which received combination of cisplatin and triptorelin;

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Efficacy outcome

    In rats with ovarian tumors, cisplatin plus triptorelin produced higher treatment pathomorphosis (10.1 ± 0.1%) than the listed monotherapies or combined hormonal drugs.

    In plain wordsIn rats with ovarian tumors, cisplatin plus triptorelin produced higher treatment pathomorphosis than the listed monotherapies or combined hormonal drugs.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTreatment pathomorphosis
    Study

    ratn: not reported in source

    Wistar rats with transplanted ascites ovarian tumor
    Comparator
    Cisplatin, triptorelin or exemestane monotherapy, or combined hormonal drugs
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Combination of cytostatic agent with triptorelin or exemestane has demonstrated significantly higher rates of treatment pathomorphosis (10.1 ± 0.1% and 16.2 ± 0.3%, respectively)
    3 context sentences
    Summary · context
    as compared with the same in rats treated in regimen of monotherapy with cisplatin, triptorelin, exemestane or by combination of hormonal drugs.
    Summary · context
    36 female Wistar rats, which underwent intraperitoneal transplantation of ascites OT (5×10(6) cells per animal), have been involved in the study.
    Summary · context
    Rats were distributed into 4 groups (9 rats in each group): group 1 - animals, which received combination of cisplatin and triptorelin;

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Efficacy outcome

    In rats with ovarian tumors, cisplatin plus triptorelin produced higher antiangiogenic activity (21.4 ± 1.4%) than the listed monotherapies or combined hormonal drugs.

    In plain wordsIn rats with ovarian tumors, cisplatin plus triptorelin produced higher antiangiogenic activity than the listed monotherapies or combined hormonal drugs.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseAntiangiogenic activity
    Study

    ratn: not reported in source

    Wistar rats with transplanted ascites ovarian tumor
    Comparator
    Cisplatin, triptorelin or exemestane monotherapy, or combined hormonal drugs
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    and antiangiogenic activity in OT (21.4 ± 1.4% and 15.0 ± 1.3%, respectively),
    3 context sentences
    Summary · context
    as compared with the same in rats treated in regimen of monotherapy with cisplatin, triptorelin, exemestane or by combination of hormonal drugs.
    Summary · context
    36 female Wistar rats, which underwent intraperitoneal transplantation of ascites OT (5×10(6) cells per animal), have been involved in the study.
    Summary · context
    Rats were distributed into 4 groups (9 rats in each group): group 1 - animals, which received combination of cisplatin and triptorelin;

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Efficacy outcome

    In rats with ovarian tumors, cisplatin plus triptorelin produced higher survival (100.0%) than the listed monotherapies or combined hormonal drugs.

    In plain wordsIn rats with ovarian tumors, cisplatin plus triptorelin produced higher survival than the listed monotherapies or combined hormonal drugs.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseSurvival
    Study

    ratn: not reported in source

    Wistar rats with transplanted ascites ovarian tumor
    Comparator
    Cisplatin, triptorelin or exemestane monotherapy, or combined hormonal drugs
    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    as well as the highest survival of animals (100.0 and 85.7%, respectively) as compared with the same in rats treated in regimen of monotherapy with cisplatin, triptorelin, exemestane or by combination of hormonal drugs.
    2 context sentences
    Summary · context
    36 female Wistar rats, which underwent intraperitoneal transplantation of ascites OT (5×10(6) cells per animal), have been involved in the study.
    Summary · context
    Rats were distributed into 4 groups (9 rats in each group): group 1 - animals, which received combination of cisplatin and triptorelin;

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.